# Botulinum Toxin Type A in the Treatment of Raynaud’s Syndrome: A Case Report

## TL;DR

A 70-year-old woman with Raynaud’s syndrome showed significant improvement after botulinum toxin type A injections, with symptoms easing within three days and lasting over three months.

## Contribution

This case report demonstrates the potential efficacy of botulinum toxin type A in treating Raynaud’s syndrome with minimal recurrence over six months.

## Key findings

- Botulinum toxin type A injections improved symptoms in a Raynaud’s syndrome patient within three days.
- The effects of the treatment lasted over three months with no recurrence observed during six months of follow-up.

## Abstract

Raynaud's syndrome is characterized by paroxysmal vasospasm in the digital arterioles, following exposure to cold or stress. Pain, swelling, stiffness, and hypoesthesia are observed as manifestations. The presence of a trophic ulcer is accompanied by a range of severe manifestations. The assaults occur in three distinct phases, namely vasospastic, plethoric, and erythema. Various approaches improve the overall well-being of a patient. It is possible to differentiate between primary and secondary Raynaud's syndrome, the latter being linked to systemic diseases. The application of botulin toxin is commonly indicated in several medical conditions including focal dystonia, spasticity with or without contractures, paraparesis in children with cerebral palsy, multiple sclerosis, brain injuries, involuntary muscle hyperactivity of a non-dystonic nature, pain management, strabismus, nystagmus, sialorrhea, and esthetic medicine. When treating Raynaud’s a technique is used with injection at the base of each finger, from the palmar side, which helps with cooling and minimizing discomfort for patients. We present a clinical case of a 70-year-old female patient with Raynaud’s syndrome in which we have placed 70E distributed to both hands botulin toxin type A. Improvement in the patient’s symptomatology was noticed on day 3, with warming of the hands, lack of swelling, and pain with duration of the effect little over three months. The patient underwent a six-month follow-up following the therapy with botulinum toxin type A, and no indications of recurrence or advancement of Raynaud's syndrome (RS) were seen.